Default Category
-
Merck: La administración de Vioxx (D)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S05Knowledge and CommunicationStarting at €5.74
-
Canadian Arrow Mines: The Nickel Price
Ron MulhollandCase IVEY-9B17M037-EEntrepreneurship, StrategyIn 2016, Canadian Arrow Mines Limited (CRO) had a promising nickel property, the Kenbridge deposit, located 70 kilometres southeast of Kenora, Ontario. The spot had been the site of significant exploration in the past. Further exploration by CRO had indicated that it could be profitable. CRO had spent close to CA$10 million on redevelopment, and needed a further $3 million for the final feasibility study before going into full operation. In 2007,...Starting at €8.20
-
De Beers Canada: The Attawapiskat Context
Ron MulhollandCase IVEY-9B16M171-EStrategyDe Beers, a sophisticated, international mining company, operated the Victor Mine, an open pit diamond mine in Canada, located within traditional territory claimed by the Attawapiskat First Nation. To develop the mine, De Beers had to follow provincial and federal legislation, meet environmental standards, and most importantly, negotiate use of the land with the First Nation. Although the mine was successful, the First Nation community was suffer...Starting at €8.20
-
Mistura Beauty Solutions
Ron Mulholland; Anthony Davis; Amanda Goupil; Christine Harvey; Kyle MarcusCase IVEY-9B12A034-EEntrepreneurship, MarketingA four-year-old cosmetics company is experiencing the typical difficulties of a company evolving from a mom-and-pop operation to a scalable, systems-driven organization. The CEO and founder recognized a problem and opportunity with foundation makeup. She developed a self-adjusting, hard-powder makeup for use on any skin tone. Following an appearance on a reality TV show for entrepreneurs and numerous other promotional measures, the company’s sale...Starting at €8.20
-
Pfizer: Letter from the Chairman (B)
Simons, Robert L.; Rosenberg, KathrynCase HBS-110004-EAccounting and ControlThis case continues the story begun in "Pfizer: A Letter From The Chairman" (HBS No. 9-110-003), revealing the letter Chairman and CEO Jeff Kindler wrote for the 2008 Annual Report.Starting at €5.74
-
Pfizer: Letter from the Chairman (A) and (B), Teaching Note
Simons, Robert L.; Rosenberg, KathrynTeaching Note HBS-110067-EAccounting and ControlTeaching Note for 110003 and 110004.Starting at €0.00
-
Managing Vioxx (A) (Spanish version)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S02Strategy(B) evidence of life-threatening side effects, (C) decision options, (D) announcement to withdraw Vioxx, (E) reaction by patients, shareholders, media, and regulators, (F) Merck fights back, and (G) wrap-up. At the end of the case series, students may conclude that doing the right thing sometimes requires very hard choices.Starting at €8.20
-
Merck: La administración de Vioxx (B)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S03Knowledge and CommunicationStarting at €5.74
-
Merck: La administración de Vioxx (C)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S04Knowledge and CommunicationStarting at €5.74
-
Merck: La administración de Vioxx (E)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S06Knowledge and CommunicationStarting at €5.74